CN1391609A - 用复制缺陷腺病毒载体加强cd8+t细胞对抗原的免疫应答 - Google Patents

用复制缺陷腺病毒载体加强cd8+t细胞对抗原的免疫应答 Download PDF

Info

Publication number
CN1391609A
CN1391609A CN00815933A CN00815933A CN1391609A CN 1391609 A CN1391609 A CN 1391609A CN 00815933 A CN00815933 A CN 00815933A CN 00815933 A CN00815933 A CN 00815933A CN 1391609 A CN1391609 A CN 1391609A
Authority
CN
China
Prior art keywords
antigen
epitope
individual
immune response
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN00815933A
Other languages
English (en)
Chinese (zh)
Inventor
J·施奈德
S·C·吉尔伯特
C·M·翰南
A·V·S·希尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10861351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1391609(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Publication of CN1391609A publication Critical patent/CN1391609A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN00815933A 1999-09-21 2000-09-20 用复制缺陷腺病毒载体加强cd8+t细胞对抗原的免疫应答 Pending CN1391609A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9922361.2A GB9922361D0 (en) 1999-09-21 1999-09-21 Generating an immune response to an antigen
GB9922361.2 1999-09-21

Publications (1)

Publication Number Publication Date
CN1391609A true CN1391609A (zh) 2003-01-15

Family

ID=10861351

Family Applications (1)

Application Number Title Priority Date Filing Date
CN00815933A Pending CN1391609A (zh) 1999-09-21 2000-09-20 用复制缺陷腺病毒载体加强cd8+t细胞对抗原的免疫应答

Country Status (12)

Country Link
EP (2) EP1612269A1 (enExample)
JP (1) JP2003509470A (enExample)
CN (1) CN1391609A (enExample)
AT (1) ATE295421T1 (enExample)
AU (1) AU762894B2 (enExample)
BR (1) BR0014138A (enExample)
CA (1) CA2384806A1 (enExample)
DE (1) DE60020136T2 (enExample)
DK (1) DK1214416T3 (enExample)
ES (1) ES2241653T3 (enExample)
GB (1) GB9922361D0 (enExample)
WO (1) WO2001021201A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100410382C (zh) * 2006-08-18 2008-08-13 上海交通大学医学院 一种可诱生细胞免疫应答的共表达载体和真核表达载体
CN104755622A (zh) * 2012-10-28 2015-07-01 巴法里安诺迪克有限公司 用于稳健t细胞和抗体应答的pr13.5启动子
CN114828878A (zh) * 2019-10-16 2022-07-29 癌症研究科技有限公司 用于癌症治疗的载体

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711957D0 (en) 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
JP2003530307A (ja) 1999-07-06 2003-10-14 メルク・アンド・カンパニー・インコーポレーテッド ｇａｇ遺伝子保有アデノウイルスＨＩＶワクチン
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
GB0118532D0 (en) * 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
JP4654026B2 (ja) * 2002-05-20 2011-03-16 独立行政法人科学技術振興機構 Ｂｃｇワクチンとその利用
EP1553983A2 (en) 2002-10-23 2005-07-20 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
JP5646851B2 (ja) * 2006-11-17 2014-12-24 ジェネトロニクス，インコーポレイティド エレクトロポレーション支援ワクチン投与及び追加投与を用いた免疫応答の増強方法
GB0706914D0 (en) * 2007-04-10 2007-05-16 Isis Innovation Novel adenovirus vectors
GB0706912D0 (en) * 2007-04-10 2007-05-16 Isis Innovation Novel viral vaccines
CA2699465C (en) * 2007-09-14 2017-11-28 Institut Pasteur Polynucleotides allowing the expression and secretion of recombinant pseudo-virus containing foreign epitopes, their production, and use
GB0823497D0 (en) 2008-12-24 2009-01-28 Isis Innovation Immunogenic composition and use thereof
EP3595705A1 (en) 2017-03-15 2020-01-22 Oxford BioMedica (UK) Limited Method
EP4444347A1 (en) 2021-12-07 2024-10-16 Barinthus Biotherapeutics (UK) Limited Vaccine boost methods and compositions
WO2024218165A1 (en) 2023-04-17 2024-10-24 Barinthus Biotherapeutics (Uk) Limited Hpv viral vector vaccine

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100410382C (zh) * 2006-08-18 2008-08-13 上海交通大学医学院 一种可诱生细胞免疫应答的共表达载体和真核表达载体
CN104755622A (zh) * 2012-10-28 2015-07-01 巴法里安诺迪克有限公司 用于稳健t细胞和抗体应答的pr13.5启动子
CN104755622B (zh) * 2012-10-28 2021-04-20 巴法里安诺迪克有限公司 用于稳健t细胞和抗体应答的pr13.5启动子
CN114828878A (zh) * 2019-10-16 2022-07-29 癌症研究科技有限公司 用于癌症治疗的载体

Also Published As

Publication number Publication date
BR0014138A (pt) 2002-05-21
WO2001021201A3 (en) 2001-10-18
DK1214416T3 (da) 2005-08-29
DE60020136D1 (de) 2005-06-16
DE60020136T2 (de) 2006-02-23
CA2384806A1 (en) 2001-03-29
JP2003509470A (ja) 2003-03-11
EP1612269A1 (en) 2006-01-04
EP1214416A2 (en) 2002-06-19
AU7302400A (en) 2001-04-24
EP1214416B1 (en) 2005-05-11
ATE295421T1 (de) 2005-05-15
AU762894B2 (en) 2003-07-10
GB9922361D0 (en) 1999-11-24
ES2241653T3 (es) 2005-11-01
WO2001021201A2 (en) 2001-03-29

Similar Documents

Publication Publication Date Title
Moore et al. Progress in DNA‐based heterologous prime‐boost immunization strategies for malaria
Gilbert et al. Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime–boost immunisation regimes
EP1335023B1 (en) Methods and reagents for vaccination which generate a CD8 T cell immune response
EP1214416B1 (en) Use of replication-deficient adenoviral vector in the manufacture of a medicament to boost cd8+ t cell immune response to antigen
Salonius et al. The road to licensure of a DNA vaccine
US20030138454A1 (en) Vaccination method
EP2379103A1 (en) Immunogenic composition and use thereof
Bruder et al. Molecular vaccines for malaria
US20100322896A1 (en) Molecular adjuvant
US11065320B2 (en) Prime target
Scheiblhofer et al. Genetic vaccination approaches against malaria based on the circumsporozoite protein
AU775973B2 (en) Methods and reagents for vaccination which generate a CD8 T cell immune response
AU2004203141B2 (en) Methods and reagents for vaccination which generate CD8 T cell immune response
Barnett et al. DNA vaccines coming of age

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned
C20 Patent right or utility model deemed to be abandoned or is abandoned